Pozen to submit revised Trexima response; shares fall
Pozen to submit revised Trexima response; shares fall
By Gabriel Madway
Last Update: 11:04 AM ET Dec 13, 2006
SAN FRANCISCO (MarketWatch) -- Pozen Inc. shares fell 16% to $15.24 in Wednesday morning trade after the Chapel Hill, N.C.-based pharmaceutical company said the Food and Drug Administration has completed its initial review of Pozen's response to the June 8 approvable letter for Trexima, and has determined the response is not yet complete. The FDA has requested additional analyses and supporting information relating to the data submitted in the November response. Pozen expects to submit the revised response before the end of the year.
By Gabriel Madway
Last Update: 11:04 AM ET Dec 13, 2006
SAN FRANCISCO (MarketWatch) -- Pozen Inc. shares fell 16% to $15.24 in Wednesday morning trade after the Chapel Hill, N.C.-based pharmaceutical company said the Food and Drug Administration has completed its initial review of Pozen's response to the June 8 approvable letter for Trexima, and has determined the response is not yet complete. The FDA has requested additional analyses and supporting information relating to the data submitted in the November response. Pozen expects to submit the revised response before the end of the year.
posted by B at 7:51 PM
0 Comments:
Post a Comment
<< Home